



VOLTAROL[®] 50

diclofenac sodium

The symbol of a new flexibility

Eases rheumatic pain and stiffness

Improves mobility

Flexible dosage

Geigy

Full prescribing information is available from
Geigy Pharmaceuticals, 54 Northumberland Road, Ballsbridge, Dublin.



How long must they wait for Froben?

Three years' use in General Practice has shown that Froben is very effective in the treatment of osteoarthritis – as it is in rheumatoid arthritis.

Froben, a potent inhibitor of prostaglandin biosynthesis, has the powerful analgesic and anti-inflammatory action needed to relieve the pain and stiffness of osteoarthritis.

Today, a substantial proportion of prescriptions for Froben are for elderly osteoarthritic patients.

The sort of patients you see almost every day.

Make Froben **your** first choice.
We strongly recommend it.

 The Boots Company Ltd., Nottingham


Froben

flurbiprofen

A power to use sooner than later

Prescribing Information:

Presentation: Sugar-coated tablets, each containing either 50mg or 100mg of flurbiprofen. **Uses:** Froben is indicated in the treatment of rheumatoid disease, osteoarthritis and ankylosing spondylitis. **Dosage:** 150mg to 200mg daily in 3 or 4 divided doses. In patients with severe symptoms or disease of recent origin, or during acute exacerbations, the total daily dose may be increased to 300mg in divided doses. **Contra-indications, Warnings etc:** Froben should not be given to patients with peptic ulceration. Care should be taken when administering the drug to patients with asthma or who have experienced bronchospasm with other anti-inflammatory or analgesic agents. The safety of Froben during pregnancy or lactation has not been established. In animal experiments, no teratogenic effects were demonstrated but parturition was delayed and prolonged. Side-effects: dyspepsia, heartburn and headache are the commonest encountered. Occasional skin rashes have been reported. Treatment of overdosage: gastric lavage and, if necessary, correction of serum electrolytes. There is no specific antidote. **Basic NHS Price:** 50mg tablets, 100 £8.24 100mg tablets, 100 £15.65. **Product Licence No:** 50mg tablets, PL0014/0167, 100mg tablets, PL0014/0168. Further information is available on request.



BONE AND JOINT DISEASES

Arthritis used to be the Cinderella of diseases, but improved diagnostic techniques, advances in joint replacement surgery, and a whole range of non-steroidal drugs have led to a much more active approach to the management of the common bone and joint diseases. Detailed advice on their diagnosis and treatment was given in a series of 16 articles in the *BMJ*, and these have been gathered together in the latest volume based on the popular "Today's Treatment" series.

Demy Octavo—Paperback—131 pages—ISBN 0 7279 0026 9

Price: Inland £3.00; Abroad US \$7.50, including postage

Payment must be enclosed with order or a surcharge of 50p will be made for rendering invoices and statements

Order your copy now from

The Publisher, BRITISH MEDICAL JOURNAL, BMA House,
Tavistock Square, London WC1H 9JR or through any leading bookseller

24-hour relief that matches the pattern of pain and stiffness

Once-daily dosage gives most arthritics:

- rapid relief of pain and stiffness
- continued control of inflammation
- well tolerated, long-term therapy
- simple dosage, increases likelihood of successful treatment

Indocid[®]-R
Sustained-release indomethacin

M

Thomas Morson Pharmaceuticals
Hemford Road, Hemditch, Hertfordshire
Division of Merck Sharp & Dohme Limited

denotes registered trademark

11-511DC 80 GB 7601 J

For prescribing information, see overleaf

The University of Liverpool

**MERSEY REGIONAL COUNCIL
FOR POSTGRADUATE
MEDICAL EDUCATION**

A.P.T.S. SANDWICH COURSE IN RHEUMATOLOGY

APRIL 1-3, 1981

Accommodation Available

DISTINGUISHED GUEST SPEAKERS

will take part and the course is approved under the
Advanced Postgraduate Training Scheme for
Senior Trainees and Consultants

Further information from:

Dr T. R. Littler,
c/o Postgraduate Dean's Office,
Faculty of Medicine,
University of Liverpool,
PO Box 147,
Liverpool L69 3BX.
Tel: 051-709 3114

University of London

**ROYAL
POSTGRADUATE MEDICAL SCHOOL**

CONNECTIVE TISSUE DISEASES

8-10 April 1981

This is a three-day course aimed at senior registrars
and consultants in rheumatology and general
medicine. It will consist of lectures, clinical
demonstrations and seminars. The emphasis will be
on vasculitis and 'overlap' syndromes.

Course organiser:
Course fee:
(including catering)


Dr G R V Hughes
£60 for home students
and member countries of
the EEC

£200 for overseas students


Application forms
may be obtained
from:

School Office (SSC),
Royal Postgraduate
Medical School,
Hammersmith Hospital,
Du Cane Road,
London, W12 0HS
Tel: 01-743 2030 ext 351

The potent anti-arthritic that's gentle on your patient



In the stomach LEDERFEN is present as fenbufen which is not a gastric irritant. In the liver, LEDERFEN is converted to long-acting metabolites which possess potent anti-inflammatory and analgesic activity.



- Exceptional gastro-intestinal tolerance
- No accumulation in patients with renal impairment
- Simple dosage
- Highly effective

Lederfen^{*}

fenbufen

The right choice for your older arthritic patients

PRESENTATION

300 mg Capsules

Dark blue capsules each containing 300 mg of fenbufen and printed "Lederle 300 mg" on both the cap and body.

USES

Lederfen is a potent non-steroidal anti-inflammatory and analgesic agent indicated for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis.

DOSAGE AND ADMINISTRATION

Adults

Two capsules (600 mg) as a single daily dose or three capsules (900 mg) daily in divided doses. Many patients can be adequately controlled with a daily dosage of two capsules taken at night, whereas some may require an extra capsule in the morning.

It is unnecessary to modify the dosage of Lederfen in cases of mild to moderate renal impairment. Lederfen may therefore be used in elderly patients in whom renal impairment commonly occurs.

Children

Not recommended for administration to children under the age of 14.

CONTRA-INDICATIONS, WARNINGS ETC.

Contra-indications: Hypersensitivity to propionic acid anti-inflammatory drugs, or aspirin.

Precautions: As with other non-steroidal anti-inflammatory agents, Lederfen should be used with great caution in patients with a history of evidence of active peptic or intestinal ulceration, and only when considered essential in pregnant and nursing women.

Warnings and adverse effects: Lederfen is well tolerated by most patients and unlike other non-steroidal anti-inflammatory agents is extremely unlikely to cause gastro-intestinal ulceration. However adverse effects may include symptoms of gastro-intestinal intolerance such as nausea. Other reactions which have occurred infrequently include skin rash, dizziness, drowsiness and headache. Slight decreases in blood leucocytes, haemoglobin, and

haematocrit, as well as slight increases in prothrombin time and eosinophils, have occasionally been recorded. Transient elevations in values of liver function tests have occurred in some patients.

Drug interactions: When single doses of aspirin 900 mg and Lederfen 500 mg are administered together, serum concentrations of Lederfen and its metabolites are reduced by 10-20%. Concomitant use of aspirin may require adjustment of dosage of Lederfen.

Lederfen is strongly protein bound. Although no clinically significant interactions have been noted as yet, practitioners should be alert to this possibility.

Overdosage: There is no experience with overdosage, consequently the signs and symptoms and treatment have not been identified. There is no specific antidote.

PHARMACEUTICAL PRECAUTIONS

Store at a temperature not exceeding 15°C in the original container. Keep lid tightly closed.

LEGAL CATEGORY

POM

PACKAGE QUANTITIES

Bottle of 100 Basic NHS cost: £16.24 per 100 capsules.

FURTHER INFORMATION

Lederfen is extremely unlikely to cause gastro-intestinal bleeding or ulceration since it is present in the stomach as fenbufen which is not a gastric irritant. Following absorption fenbufen is converted into active metabolites whose prolonged duration of action (half-lives 10-17 hours) provide sustained anti-inflammatory and analgesic activity. Therefore in many patients single oral doses given at night will provide adequate plasma levels to provide symptomatic relief of nocturnal pain and morning stiffness.

PRODUCT LICENCE NUMBER
0095 0043

PRODUCT AUTHORISATION NUMBER
37 26 2

DATE OF PREPARATION OR
LAST REVIEW

November 1980

* Trademark

Further information is available on request to the company.



Lederle Laboratories, a division of Cyanamid of Great Britain Limited
Fareham Road, Gosport, Hants PO13 0AS Tel: (0329) 236131.

METHRAZONE[®] HAS THE STRENGTH

feprazone

There's a strong case for including Methrazone in your armamentarium of anti-arthritic agents. Methrazone reinforces your choice of treatment, providing effective relief from the chronic problem of pain, stiffness, inflammation and immobility.

Unlike many other anti-arthritic agents introduced in recent times, Methrazone is founded on strength. Chemically its starting point lies in phenylbutazone. But Methrazone is a whole generation different from phenylbutazone – chemically and clinically. Its one strong similarity to phenylbutazone is a high degree of anti-inflammatory activity.

As befits a modern anti-arthritic, Methrazone has a low incidence of major adverse effects – and has stood up strongly to a particularly searching scrutiny of its safety in short- and long-term monitored programmes. Adding Methrazone to the armamentarium can only strengthen your choice.

PRESCRIBING INFORMATION: Methrazone – feprazole capsules 200mg

Action and Indications: Non-steroidal anti-inflammatory agent for rheumatoid arthritis and osteoarthritis. **Contra-indications:** Where there is a danger of cardiac decompensation; hepatic disease; history of peptic ulceration; blood disorders; drug rash or known sensitivity to pyrazoles.

Precautions, Warnings and Side effects: Caution in therapy with plasma protein bound agents; as for all pyrazole drugs, blood monitoring and surveillance for sodium and water retention are advised; caution in pregnancy during organogenesis. Mild gastric intolerance, rashes, and occasional headache have been reported. **Dosage:** Adults – 200-600mg daily in divided doses by mouth after food. **Pack size and basic NHS price:** UK only 100 capsules, £9.95.

PL 0015 0071 ▼ For full prescribing information please see data sheet.

WB Pharmaceuticals Ltd PO Box 25 Bracknell, Berkshire RG12 4YS



REALLY ACTIVE IN ARTHRITIS



Presentation MERALEN 100mg
Hard gelatin capsule with light
blue body and dark blue cap.
Composition Each 100mg
capsule contains Flufenamic Acid
BP 100mg

Action MERALEN is an anti-
inflammatory analgesic known
chemically as N-(4-oxo-1-fluoreno-
methyl)anthranic acid.

Indications For the relief of pain
in rheumatoid arthritis,
osteoarthritis and ankylosing
spondylitis.

Dosage and administration
(Oral) **Adults** 600mg daily in
divided doses, preferably with
food. After four weeks continuous
therapy reduced maintenance
dosage of 400mg daily may be
satisfactory in some patients. For
those weighing less than 45kg
(100 lb) dosage should not
exceed 10mg per kg body weight
daily. **Children** MERALEN should
not be given to children under 14
years or less.

**Contra-indications, warnings,
etc.** Contra-indicated in
pregnancy, in inflammatory bowel
disease and in patients suffering
from gastric and/or intestinal
ulceration and intestinal colitis
disease.

Precautions Concurrent therapy
with other pharmaceuticals and
drugs, e.g. anticoagulants may
necessitate a modification of
dosage.

Warnings and Adverse Effects
Discontinue administration of
MERALEN if any of the following
abnormalities occur, for as long as
they occur. The commonest side effect
is gastrointestinal upset.

Characteristically nausea, vomiting
and epigastric discomfort, gastro-
intestinal intolerance, constipation and
the physical attributes of the drug
may be relieved by either the
dosage and symptoms do not subside. The
drug may need to be discontinued
discontinued. The physician may
be able to increase the daily
dosage of MERALEN and if these
symptoms have subsided in
some patients the gastro-
intestinal symptoms subside
spontaneously without reduction
of dosage of MERALEN.

MERALEN should be discontinued
in the event of rash suspected
to be a sensitivity reaction. Occurrence
of purpura and febrile convulsions
have been reported, one of the
latter had been of a severe
spontaneous nature. If either of
MERALEN therapy had
commenced. Bronchospasm may
be precipitated in patients
suffering from asthma with previous
history of bronchial asthma or
allergic disease.

Treatment of overdosage
Gastric lavage in the conscious
patient and ipecacuanide if on
therapy where necessary.
Activated charcoal has been
shown to be a powerful adsorbent
for MERALEN and is suitable for
studies in experimental animals
showed that a high level of
charcoal res adsorbed the oral
suppression of absorption of the
drug.

Pharmaceutical precautions
No special storage precautions.

Legal category

Package Quantities 100mg
capsules available in packs of
100 capsules.

Basic NHS cost £4.40 (100
capsules) June 1978

Product Licence No. MERALEN
Capsules 100mg (1977) 10032

References 1. *Journal of*
Rheumatology 1976
Supplement to December 1976
Collier P.E. (1970) *Medical*
Proceedings 16, 341

Merrel Division, Rugby, Britain
Merrel Ltd, 20 Queensway,
Sough, Berks, SL1 1YJ

Merrel and Meraleen are trade
marks.

Anti-inflammatory Analgesic Capsules Flufenamic Acid BP

the valid alternative in arthritis

You and your arthritic patient will have
experienced the time-consuming search
through the available non-steroidal
armamentarium for the drug "... which
combines optimal effectiveness and absence
of adverse effects".

MERALEN may just be the right drug for many
of your arthritic patients

MERALEN belongs to the fenamates, totally
unrelated to the propionic acid derivatives,
salicylates and phenyl-pyrazolone derivatives

"Flufenamic acid (**MERALEN**) appears to be
useful as an anti-rheumatic drug, especially in
rheumatoid and osteo-arthritis, where
long-standing pain and joint inflammatory
processes were still active. It gives relief and
even enhances mobility where joint pathology
incapacitates movement".²

in arthritis

FLENAC

fenclofenac

a step beyond symptomatic relief

Flenac is not only a first-class treatment for arthritic pain and inflammation; recent studies¹⁻⁴ point to an extra benefit not shared by other non-steroidal anti-inflammatories.


These studies show Flenac to have a beneficial effect on E.S.R. and on C-reactive protein and Rheumatoid Factor titres – the laboratory parameters considered to best reflect disease activity and correlate with radiological evidence of joint damage⁵

reducing eventual joint damage



relieving pain and inflammation

Prescribing information: Presentation: 100mg and 200mg tablets. Indications: Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis, Gout, Pain relief. **Contra-indications:** Hypersensitivity to fenclofenac or any of the excipients, active peptic ulcer, severe renal or hepatic impairment, pregnancy and lactation. **Warnings:** Patients should be warned of the risk of gastrointestinal bleeding, especially in the elderly. **Side-effects:** Headache, dizziness, nausea, vomiting, diarrhoea, constipation, flatulence, indigestion, abdominal pain, rash, pruritus, urticaria, photosensitivity. **Note:** Flenac is a non-steroidal anti-inflammatory drug (NSAID). **P.L.:** 001/001/001. **References:** 1. J. Pharm. Med. (1991) 1, 1-4. 2. J. Pharm. Med. (1991) 1, 5-8. 3. J. Pharm. Med. (1991) 1, 9-12. 4. J. Pharm. Med. (1991) 1, 13-16. 5. J. Pharm. Med. (1991) 1, 17-20. **N.H.S. Price:** 100mg tablets, 100p; 200mg tablets, 150p. **280**



TRILISATE®

CHOLINE MAGNESIUM TRISALICYLATE TABLETS

FOR ARTHRITIS



From now on,
aspirin is only for headaches.

PRESCRIBING INFORMATION:

PRESENTATION: Pale orange capsule-shaped, scored tablets with TRILISATE on one side and NAPP 500 on the other, containing 500mg salicylate as choline magnesium trisalicylate.

USES: TRILISATE tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and other arthroses.

DOSAGE AND ADMINISTRATION:

Two tablets twice a day for osteoarthritis and mild to moderate arthroses. Three tablets twice a day for rheumatoid arthritis and the more severe arthroses.

CONTRA-INDICATIONS, WARNINGS, ETC.

CONTRA-INDICATIONS: Hypersensitivity

to aspirin. Active peptic ulceration. Haemophilia.

PRECAUTIONS: Concurrent administration with other analgesics containing aspirin.

As with other salicylates, TRILISATE tablets should be used with caution in patients with chronic renal insufficiency, or with erosive gastritis or peptic ulcer.

TRILISATE tablets should be used with caution in pregnancy.

WARNINGS AND ADVERSE EFFECTS:

May induce gastro-intestinal haemorrhage. Reports indicate that when salicylates are given with steroids, the butazones or alcohol, the risk of gastro-intestinal ulceration is increased.

TRILISATE tablets are not recommended for

children under twelve years of age. As with all medicines, TRILISATE tablets should be kept out of reach of children.

TREATMENT OF OVERDOSAGE:

Empty stomach contents and lavage stomach with 5% sodium bicarbonate solution.

Severe overdosage should be treated by diuresis induced by intravenous saline with sodium bicarbonate, or dextrose solution.

Electrolyte levels and acid base balance should be monitored and corrected as necessary.

PHARMACEUTICAL PRECAUTIONS:

TRILISATE tablets should be stored in a cool, dry place, protected from light.

LEGAL CATEGORY: P.

PACKAGE QUANTITIES: Containers of 60 tablets.

FURTHER INFORMATION:

When TRILISATE tablets are administered, the salicylate is absorbed rapidly and reaches peak blood levels within two hours. At recommended doses, the therapeutic range of 5 to 30mg/100ml is achieved, and a steady state condition is normally reached after 4-5 doses.

TRILISATE tablets do not cause any significant faecal blood loss nor do they affect platelet aggregation.

TRILISATE tablets do not cause any observable stomach mucosal irritation as determined by endoscopic examination.

Basic NHS cost: 27.5p/day (2 b.d.)

NAPP

Further information is available on request from Napp Laboratories Limited, Hill Farm Avenue, Watford WD2 7RA, England.
Member of Napp Pharmaceutical Group. ® Trilisate is a registered trade mark. © Napp Laboratories Limited 1980. P.L. 0337/0053.

Pain relieving power in harness

BRUFEN 400

Ibuprofen B.P.

The Great British Workhorse in arthritis

PUZZLED PRESCRIBER:

*Horses? A Ploughman?
Are you indicating that
these rural operatives are
more than usually prone
to rheumatic ailments?*

AGRONOMICALLY INCLINED ADVERTISER:

It occurred to us that, as a Physician, you would not be greatly attracted by photographic depictions of simulated surgery scenes and the like. Our amiable rustic and his equine colleagues are intended to convey analogically that, when it comes to the treatment of painful rheumatic conditions (be it in urban or rural practice), Brufen is a most efficient and reliable drug.



1 tablet
3-4 times
daily

Prescribing Information. **Presentation** Brufen 400 are sugar-coated tablets each containing 400mg of ibuprofen B.P. The tablets are light magenta in colour and bear the overprint 'Brufen 400' in black. **Uses** Brufen is indicated for its anti-inflammatory and analgesic effect in the treatment of rheumatic disorders including juvenile rheumatoid arthritis or Still's disease,ankylosing spondylitis,osteoarthritis and other non-rheumatoid seronegative arthropathies. In the treatment of non-articular rheumatic conditions Brufen is indicated in particular conditions such as frozen shoulder, capsitis, bursitis, tendinitis, tenosynovitis and low back pain. It can also be used in soft tissue injuries such as sprains and strains. **Dosage and Administration Adult:** The recommended initial dosage of Brufen is 1200 mg daily in divided doses. Some patients can be maintained on 600 to 1200 mg daily. It can be advantageous in severe conditions to increase the dosage to 1600 mg daily in divided doses until the acute phase is brought under control. **Children:** 20 mg of Brufen per kg of body weight daily, except that in children weighing less than 20 kg the total dose of Brufen given in 24 hours should not exceed 500 mg. **Contra-indications** Brufen should not be given to patients with severe or active peptic ulceration. **Use in Pregnancy** No teratogenic effects have been demonstrated in animal experiments; nevertheless, the use of Brufen during pregnancy should be avoided if possible. **Warnings and Adverse Effects** Brufen should be prescribed with caution for patients with asthma and especially for those who have developed bronchospasm with other non-steroidal agents. The adverse effects reported include dyspepsia, gastrointestinal intolerance and bleeding and skin rashes of various types. Less frequently thrombocytopenia has occurred. A very rare occurrence can be toxic amblyopia, but in reported cases recovery occurred upon cessation of treatment. **Treatment of Overdosage** Gastric lavage, if necessary, correct oral and subcutaneous. **Further Information** When Brufen is taken on an empty stomach the peak serum levels occur 45 minutes after ingestion, whereas when taken after a meal the peak is delayed to 90 minutes. Consequently, as most patients can take Brufen on an empty stomach without gastric discomfort, the first daily dose is taken on awakening with a drink, the rapid absorption of the drug will be maintained and the risk of gastric distress. **Basic NHS Price** Brufen 400 (200 Tablets) £10.94 **Product Licence Numbers** 400 mg tablets Brufen 400

NIAGARA THERAPY

are manufacturers of a wide range
of medically proven therapeutic
equipment for the relief of
RHEUMATIC & ARTHRITIC PAIN

NIAGARA THERAPY

reduces swelling due to
excess tissue fluid, in-
creases blood circulation
and joint mobility

NIAGARA THERAPY

were chosen as suppliers of
therapy equipment for the 1980
Winter & Summer Olympic Games

NIAGARA THERAPY

are sponsors of the Borocourt Hospital
project on retarded children, and the Sports
Injury Clinic at Bristol Royal Infirmary—
just two of the ongoing research
programmes in which the company is
involved.



Official Supplier to the 1980
Olympic Games in Moscow

for further information and
reports, contact David Horchover,
Group Marketing Manager,

NIAGARA THERAPY (UK) LIMITED
251 Vauxhall Bridge Road, London SW1V 1HG
Phone: 01-828 8701

**AS INTERNATIONAL SUPPLIERS, WE ALWAYS
WELCOME EXPORT AND OVERSEAS ENQUIRIES**

Diseases of Connective Tissue

*The Proceedings of a Symposium organized by
The Royal College of Pathologists*

Edited by D. L. Gardner

The cells—Fibroblasts ● Chondrocytes ●
Synoviocytes ● The muscle cell ● **Extra-
cellular materials**—Collagens ● Collagen and
elastin fibres ● Basement membrane ● Pro-
teoglycans of cartilage ● **Disease mechanisms**
—Diseases of the collagen molecule ●
Molecular abnormalities of collagen ● Lyso-
somes and the connective-tissue diseases ●
Genetic disease—HLA system and rheumatic
disease ● Replacement therapy in the muco-
polysaccharidoses ● Genetic disease and
amyloid ● **Inflammation and fibrosis**—
Rheumatoid arthritis—a virus disease? ●
Systemic lupus erythematosus—an auto-
immune disease? ● Hepatic cirrhosis—a
collagen formative disease? ● Fibrosis of
lung—an environmental disease? ● **Kettle
Memorial Lecture**—Atherosclerosis—disease
of old age or infancy? ● **Structural and
metabolic disease**—New knowledge of con-
nective tissue ageing ● New knowledge of
osteoarthritis ● New knowledge of inter-
vertebral disc disease ● New knowledge of
the pathogenesis of gout ● New knowledge of
chondrocalcinosis ● **A consensus**—Connective
tissue diseases: A consensus

**Price: Inland £6.00;
Abroad US\$15.00,
including postage**

Payment must be enclosed with order or a surcharge of 30p
will be made for rendering invoices and statements

The Publisher, *Journal of Clinical Pathology*,
B.M.A. House, Tavistock Square, London
WC1H 9JR

The combination of
simple language and straightforward
line drawings has made the


ABC OF OPHTHALMOLOGY

one of the most popular series
of articles in the Medical Practice section
of the British Medical Journal.

All the common problems are covered -
visual defects, squints, glaucoma and
cataracts - together with detailed
instruction on examination, diagnosis
and management.

The articles
have now been
collected into book
form - in exactly
the same format
as they appeared in
the BMJ -
price: Inland £2.50;
Overseas US\$6.25
(Inland £2.00;
Overseas US\$5.00
for BMA members).

Order your copy now
From: The Publisher,
British Medical Journal,
BMA House,
Tavistock Square,
London WC1H 9JR
or any leading bookseller




STATISTICS by T. D. V. SWINSCOW AT SQUARE ONE

from the **British Medical Journal**

The statistical testing of data is indispensable in many types of medical investigation and a help on countless occasions in clinical practice. This book provides step-by-step instruction. Subjects covered include standard deviation, χ^2 tests, t tests, non-parametric tests, and correlation. The book includes sections on Fisher's exact probability test and rank correlation not published in the *B.M.J.* series. Methods specially adapted to pocket calculators.

"The ability to put symbols in sequence may well be one of the greatest advances in man's development . . . This excellent and attractive volume will give you an idea into which category an article or projected article fits. The ink you save may be your own. It is superb value."
O'Donnell, Barry, *British Medical Journal*, 1977, 1, 451.

" . . . this gem of a practical booklet squeezes the essence of biostatistics into 75 well-written, well-organized pages. Newcomers to the field will like the way obscure concepts are clarified; experts will find the book valuable as a teaching aid."
de Jong, Rudolph, H., *J.A.M.A.*, 1977, 237, 1874.



**Seventh edition
Now available**

PRICE: Inland £2.50

Overseas US\$10.00
including postage
by air mail

Payment must be enclosed with order or a surcharge of 50p will be made for rendering invoices and statements

ORDER YOUR COPY NOW

*From: The Publisher,
British Medical Journal,
BMA House,
Tavistock Square,
London WC1H 9JR*

or through any leading bookseller